A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer

Journal of Nuclear Medicine

Volumn 46, Issue 4, 2005, Pages 620-633

  Sharkey, Robert M ^a   Hajjar, George ^a   Yeldell, Dion ^a   Brenner, Arnold ^a   Burton, Jack ^a   Rubin, Arnold ^b   Goldenberg, David M ^a,c  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

Carcinoembryonic antigen; Chemotherapy; Dosimetry; Medullary thyroid cancer; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DOXORUBICIN; INDIUM 111; LABETUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; YTTRIUM 90; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; FEMALE; HUMAN; HYPERTENSION; ISOTOPE LABELING; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TOXICITY; URTICARIA; ADULT; AGED; BODY BURDEN; METABOLISM; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RADIATION RESPONSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; RISK ASSESSMENT; RISK FACTOR; THYROID TUMOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BODY BURDEN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK ASSESSMENT; RISK FACTORS; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 19644379671     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Robbins J, Merino MJ, Boice JD Jr, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991;115:133-147.
2. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
3. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305-310.
4. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine: Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 2000;83:715-718.
5. Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994;5:763-765.
6. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer. 1994;73:432-436.
7. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
8. Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose adriamycin. Br J Clin Pract. 1990;44:517-518.
9. Petursson SR. Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer. 1988; 62:1899-1903.
10. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol. 1990;57:55-64.
11. Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma: an immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657-662.
12. Juweid M, Sharkey RM, Behr T, et al. Improved detection of medullary thyroid carcinoma with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol. 1996;14:1209-1217.
13. Juweid ME, Sharkey RM, Behr T, et al. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with I-131-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 1995;55:5946-5951.
14. 2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab. 1992;74:157-163.
15. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1993;34:1267-1273.
16. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-1842.
17. 2 anti-carcinoembryonic antigen (CEA) monoclonal antibody and autologous hematopoietic stem cell rescue (AHSCR). J Nucl Med. 2000;41:93-103.
18. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995;55:5935s-5945s.
19. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44:77-84.
20. Behr TM, Wulst E, Radetzky S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radio-resistant tumor type. Cancer Res. 1997;57:5309-5319.
21. Stein R, Juweid M, Zhang C-H, Goldenberg DM. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin Cancer Res. 1999;5(suppl):3199s-3206s.
22. Stein R, Chen S, Reed L, Richel H, Goldenberg DM. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer. 2002;94:51-61.
23. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
24. Siegel JA, Wu RK, Maurer AH. The buildup factor: effects of scatter on absolute volume determination. J Nucl Med. 1985;26:390-394.
25. 2 fragments in humans. In: Schlafke-Stelson A, Watson EE eds. Proceedings of the Fourth International Radiopharmaceutical Dosimetry Conference. Oak Ridge, TN: Oak Ridge Associated Universities; 1985:464-476.
26. 90Y-labeled antibodies [abstract]. J Nucl Med. 2001;42(suppl):22P.
27. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
28. International Commission on Radiological Protection. Report of the Task Group on Reference Man. ICRP Publication 23. New York, NY: Pergamon Press; 1975.
29. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31-42.
30. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol. 2003;4:339-347.
31. 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19:65-71.
32. Drosten M, Putzer BM. Gene therapeutic approaches for medullary thyroid carcinoma treatment. J Mol Med. 2003;81:411-419.
33. Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA, Seissler J. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother. 2002;51:663-668.
34. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5(suppl):3190s-3198s.
35. Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003:9(Pt 2):3973S-3981S.
36. Mirallié E, Vuillez JP, Bardet S, et al. High frequency of bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-788.
37. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
38. 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6:3095-3102.
39. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
40. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000;6:3855-3863.
41. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806-2811.
42. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9:5842-5852.
43. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993; 329:1219-1224.
44. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity, Proc Natl Acad Sci USA. 2000;97:1802-1807.
45. 131I- labeled bivalent hapten. J Nucl Med. 2000;41:480-487.
46. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
47. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63: 354-363.
48. Fersht N, Vini L, A'Hern R, Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid. 2001;11:1161-1168.